Application 210632
- Type
- NDA
- Sponsor
- FRESENIUS KABI USA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | SOLUTION;INTRAVENOUS | 100MCG/5ML (20MCG/ML) | Yes | Yes |
| 002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | SOLUTION;INTRAVENOUS | 200MCG/5ML (40MCG/ML) | Yes | Yes |
| 003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | SOLUTION;INTRAVENOUS | 500MCG/5ML (100MCG/ML) | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N210632-001 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | |
| N210632-002 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | |
| N210632-003 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | |
| N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | |
| N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | |
| N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | |
| N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | |
| N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | |
| N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | |
| N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | |
| N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | |
| N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | |
| N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | |
| N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2020-12-22 03:56 UTC | 2020-12 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 6a51e52b5d6a… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 6a51e52b5d6a… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 1c564ffb4f44… | |
| 2024-02-18 07:12 UTC | 2024-02 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 1c564ffb4f44… | |
| 2024-02-18 07:12 UTC | 2024-02 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | ea1830bbd6c7… | |
| 2023-12-20 04:57 UTC | 2023-12 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | ea1830bbd6c7… | |
| 2023-12-20 04:57 UTC | 2023-12 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | a72a2bbeb626… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | a72a2bbeb626… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 9b2671bbb829… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 9b2671bbb829… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | a67488948f0b… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | a67488948f0b… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3f0d92c62455… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3f0d92c62455… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 053a50430f4f… | |
| 2023-05-13 08:27 UTC | 2023-05 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 053a50430f4f… | |
| 2023-05-13 08:27 UTC | 2023-05 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N210632-001 | LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3bdfa0b2c4d7… | |
| 2023-01-26 05:58 UTC | 2023-01 | N210632-002 | LEVOTHYROXINE SODIUM | 200MCG/5ML (40MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3bdfa0b2c4d7… | |
| 2023-01-26 05:58 UTC | 2023-01 | N210632-003 | LEVOTHYROXINE SODIUM | 500MCG/5ML (100MCG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-04-11 | 3bdfa0b2c4d7… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-002 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N210632-003 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 10398669 | 2036-12-01 | Drug product | 2019-09-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 11135190 | 2036-12-01 | Drug product | 2021-10-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 12636270 | 2036-12-01 | Drug product | 2026-06-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N210632-001 | 9782376 | 2036-12-01 | Drug product | 2019-06-11 | caaa826d4ba7… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Fresenius Kabi USA, LLC | 08f4b1f8-6807-47e7-bef8-8d1972aa0557 | 2025-03-17 | Boxed warning, Warnings, Adverse reactions | 210632 NDA210632 63323-885 63323-895 63323-890 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Fresenius Kabi USA, LLC | 388a1f15-8c1c-46a5-997f-7f326f696b59 | 2020-12-04 | Boxed warning, Warnings, Adverse reactions | 210632 NDA210632 63323-885 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Fresenius Kabi USA, LLC | 50b1c8a4-75b6-49c8-80fc-3841ee80b183 | 2020-12-04 | Boxed warning, Warnings, Adverse reactions | 210632 NDA210632 63323-885 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 63323-885 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-885 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-885 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-890 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |
| 63323-895 | Levothyroxine Sodium | Levothyroxine Sodium | Fresenius Kabi USA, LLC | NDA | Current |